Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $469,222.08 in Stock

Key Points

• Insider sale: EVP Joy Liu sold 1,104 shares on May 1 under a Rule 10b‑5 plan at an average $425.02 for $469,222.08, trimming her stake by 5.06% to 20,729 shares (≈$8.81M); she also sold 978 shares on April 1.
• Q1 results and sentiment: Vertex beat EPS estimates ($4.47 vs. $4.24) with $2.99B revenue (up 8.3% YoY) and reiterated FY2026 revenue guidance around $13.0–13.1B, while analysts remain largely positive (consensus "Moderate Buy", average price target $554.83) despite some near‑term downgrades.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) EVP Joy Liu sold 1,104 shares of the business's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $425.02, for a total transaction of $469,222.08. Following the completion of the transaction, the executive vice president owned 20,729 shares of the company's stock, valued at approximately $8,810,239.58. This represents a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joy Liu also recently made the following trade(s):

• On Wednesday, April 1st, Joy Liu sold 978 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $449.17, for a total transaction of $439,288.26.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX traded down $5.49 during trading hours on Tuesday, hitting $424.36. The stock had a trading volume of 1,905,665 shares, compared to its average volume of 1,400,388. The firm has a 50-day moving average price of $453.82 and a 200 day moving average price of $449.48. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $507.92. The firm has a market capitalization of $107.94 billion, a price-to-earnings ratio of 27.68, a PEG ratio of 1.84 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm had revenue of $2.99 billion during the quarter, compared to analysts' expectations of $2.99 billion. During the same period in the previous year, the business posted $4.06 EPS. The business's revenue was up 8.3% compared to the same quarter last year. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post 16.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Motiv8 Investments LLC purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $26,000. Swiss RE Ltd. purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $28,000. Eagle Bay Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $29,000. IMG Wealth Management Inc. grew its holdings in shares of Vertex Pharmaceuticals by 277.8% during the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company's stock worth $31,000 after buying an additional 50 shares in the last quarter. Finally, Colonial Trust Co SC grew its holdings in shares of Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on VRTX. Morgan Stanley boosted their target price on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an "overweight" rating in a research note on Tuesday. Jefferies Financial Group began coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, March 10th. They issued a "buy" rating and a $580.00 price target for the company. Wolfe Research raised shares of Vertex Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $548.00 price target for the company in a report on Tuesday, January 6th. Maxim Group raised shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and set a $575.00 price target for the company in a report on Wednesday, March 18th. Finally, Oppenheimer boosted their price target on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an "outperform" rating in a report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $554.83.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 financials showed underlying strength — non‑GAAP EPS beat consensus and product revenue grew ~8% year‑over‑year, driven by cystic fibrosis and new products; management reiterated FY2026 revenue guidance around $13.0–13.1B. Vertex tops profit estimates as sales of new cystic fibrosis drug surge
• Positive Sentiment: Management highlighted pipeline progress and contribution from new disease‑area products (CASGEVY, KASJEVY/GERNAVICS), which management says accounted for a meaningful share of recent product growth — a potential multi‑year revenue driver beyond CF. VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth
• Neutral Sentiment: The full earnings call transcript, slide deck and summaries are available for investors to review management’s details on commercial execution and R&D timelines (useful for modeling but not new info). Vertex (VRTX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Concise call summaries (Moby, TipRanks) reiterate execution themes and R&D updates; these help refine timing assumptions but do not alter guidance. Vertex Q1 2026 Earnings Call Summary
• Negative Sentiment: Several analysts trimmed price targets and updated forecasts after the report, citing mixed top‑line/EPS read and cautious near‑term expectations — analyst downgrades/target cuts are pressuring sentiment. These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
• Negative Sentiment: Some data providers reported revenue/EPS slightly below certain consensus figures and highlighted extensive insider selling and large institutional rebalances — factors that can amplify near‑term downside even if fundamentals remain intact. Vertex (VRTX) Stock Falls on Q1 2026 Earnings

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.